Daxor Corporation, a medical device company, provides biotechnology and cryobanking services in the United States. The company offers BVA-100 Blood Volume Analyzer, an instrument that measures blood volume in human body. BVA-100 Blood Volume Analyzer is used to diagnose and treat patients in various medical and surgical conditions, including congestive heart failure, critical care medicine and intensive care unit medicine, hypertension, syncope, pre-operative blood screening for hidden anemia, anemia in cancer patients, kidney failure, and hyponatremia. It also provides semen banking, blood storage, andrology, and general lab testing services. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was founded in 1970 and is headquartered in New York, New York.
Industry, Sector and Symbol
Industry Medical Instruments & Supplies
Sub-IndustryN/A
SectorMedical
Phone+1-212-3308500
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Daxor (NYSEAMERICAN:DXR) Frequently Asked Questions
What is Daxor's stock symbol?
Daxor trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "DXR."
Has Daxor been receiving favorable news coverage?
News articles about DXR stock have been trending somewhat negative this week, InfoTrie reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Daxor earned a coverage optimism score of -1.1 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near future.
Are investors shorting Daxor?
Daxor saw a decrease in short interest during the month of February. As of February 28th, there was short interest totalling 236,283 shares, a decrease of 8.7% from the February 15th total of 258,809 shares. Based on an average daily volume of 29,158 shares, the short-interest ratio is currently 8.1 days. Approximately 30.1% of the shares of the company are short sold. View Daxor's Current Options Chain.
Who are some of Daxor's key competitors?
Some companies that are related to Daxor include Tristel (TSTL), SDI (SDI), InfuSystem (INFU), TSO3 (TOS), Retractable Technologies (RVP), IsoRay (ISR), IsoRay (ISR), Omega Diagnostics Group (ODX), Milestone Scientific (MLSS), Relevium Technologies (RLV), Impression Healthcare (IHL), Vigil Health Solutions (VGL), Akers Biosciences (AKR), ANSELL LTD/S (ANSLY) and CONVATEC GRP PL/ADR (CNVVY).
What other stocks do shareholders of Daxor own?
Who are Daxor's key executives?
Daxor's management team includes the folowing people:
- Mr. Michael Richard Feldschuh, Chairman, Pres & CEO (Age 50)
- Mr. Jonathan Adam Feldschuh, Chief Scientific Officer & Director (Age 54)
- Mr. Robert J. Michel CPA, Chief Financial Officer (Age 62)
- Ms. Kathryn A. Kornafel, VP of Marketing & Commercial Devel.
- Mr. Guido Manzo, VP of Sales
How do I buy shares of Daxor?
Shares of DXR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Daxor's stock price today?
One share of DXR stock can currently be purchased for approximately $12.26.
How big of a company is Daxor?
Daxor has a market capitalization of $45.72 million.
What is Daxor's official website?
How can I contact Daxor?
Daxor's mailing address is 350 5th Ave Ste 4740, NEW YORK, NY 10118-0002, United States. The company can be reached via phone at +1-212-3308500.
MarketBeat Community Rating for Daxor (NYSEAMERICAN DXR)
MarketBeat's community ratings are surveys of what our community members think about Daxor and other stocks. Vote "Outperform" if you believe DXR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DXR will underperform the S&P 500 over the long term. You may vote once every thirty days.
